Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...

News and commentary from the world of gastroenterology and hepatology ...

AbbVie today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children ...

The study, published in JAMA Network Open, found the relative risk for inflammatory bowel disease (IBD) was about 8% higher in kids whose mothers took prescription proton pump inhibitors (PPI) or H2 ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...

Hyperbaric oxygen therapy was well tolerated in treatment-refractory ulcerative colitis and enhanced clinical outcomes alongside improved bowel perfusion.

Among biologic-naive patients with moderate to severe ulcerative colitis, upadacitinib and infliximab had the quickest onset ...

By Puyaan Singh June 29 (Reuters) - Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, sending U.S.-listed shares of the ...

Paneth cell metaplasia (PCM), long viewed as a consequence of chronic inflammation in ulcerative colitis, may also help ...